Shots:

• The companies collaborated to evaluate the safety, PK & preliminary efficacy of ATG-017 + Opdivo in the P-I/II (ERASER) trial in patients with advanced solid tumors with identified mutations in the RAS-MAPK pathway. The companies plan to initiate the patient's enrollment in H1’22
• Antengene gets the commercial & development rights globally to ATG-017 & will be responsible to sponsor & fund the study while BMS will provide Opdivo for the combination dose-escalation & dose-expansion portions of the trial
• The collaboration is based on Antengene's preclinical results which showed improved efficacy in preclinical immune CPI-resistant cancer models with the combination of ATG-017 and Opdivo

Ref: PR Newswire | Image: Antengene